The authors regret to have mistakenly placed the figure of body weight change in mice treated with different agents in PC9 cells ([Figure 6](#f0005){ref-type="fig"}*A*, *right*) with that of PC9/gef B4 cells ([Figure 6](#f0005){ref-type="fig"}*B*, *right*) during the art work. The corrected [Figure 6](#f0005){ref-type="fig"} was attached below. The authors would like to apologize for any inconvenience caused.

![Antitumor activity of BO-1978 in EGFR mutant NSCLC xenografts. Aliquots of 5 × 10^6^ PC9 (A), PC9/gef B4 (B), H1650 (C), and H1975 (D) cells were subcutaneously implanted in nude mice. When tumor sizes reached approximately 100 mm^3^, the mice were treated with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), gefitinib (10 mg/kg, daily for 5 consecutive days), BO-1978 + gefitinib, or cisplatin (6 mg/kg, three times every 4 days). The tumor volumes and body weights were monitored at the indicated times.](gr1){#f0005}
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